Form 4: ResMed Director Awarded 536 Restricted Stock Units

ResMed Inc. Director Nicole Mowad-Nassar was awarded 536 Restricted Stock Units, vesting by November 2026.

Summary

• Director Nicole Mowad-Nassar of ResMed Inc. (RMD) was awarded 536 shares of common stock on November 20, 2025.
• These shares represent Restricted Stock Units (RSUs), which were granted at a price of $0 per share.
• The RSUs are scheduled to vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.
• Following this transaction, Ms. Mowad-Nassar beneficially owns a total of 777 shares of ResMed Common Stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation event. The award of equity to a director generally aligns their interests with shareholders, which is a positive for corporate governance, but it does not reflect new operational performance.

Positives

• The award of Restricted Stock Units to a director aligns management and director interests with long-term shareholder value.
• Equity-based compensation for directors is a common practice that incentivizes performance and retention.

Negatives

• The director will not realize cash value from these RSUs until they vest and are potentially sold, subjecting the value to future stock price fluctuations.

Risks

• The ultimate value of the Restricted Stock Units is contingent on ResMed's stock performance until the vesting date.

Future Outlook

This filing primarily details a past equity award and its future vesting schedule, rather than providing forward-looking statements on the company's operational or financial performance.

Industry Context

Equity awards such as Restricted Stock Units are a standard component of director compensation across various industries, including medical devices and healthcare technology. This practice is designed to align the interests of directors with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• The use of Restricted Stock Units for director compensation is a common practice, comparable to compensation structures seen at other medical technology companies like Philips (PHG) or Zimmer Biomet (ZBH).
• Granting equity at a $0 price is typical for RSU awards, reflecting compensation for service rather than a direct purchase.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity award to a director can be viewed positively as it strengthens the alignment of the director's financial incentives with the company's long-term performance and shareholder value creation.

Next Steps

• The 536 Restricted Stock Units are expected to vest on or before November 11, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity award to an existing director, which is a standard compensation practice and does not introduce new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It reflects ongoing corporate governance and compensation structures.

Keywords

ResMed, RMD, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Award, Insider Transaction